Market Place
Sourcing Support
MannKind Corp. Q3 2024 Results & Business Update
07 Nov 2024 //
GLOBENEWSWIRE
MannKind to Present at 2024 UBS Healthcare Conference
05 Nov 2024 //
GLOBENEWSWIRE
MannKind`s Ph 1 Trial of Nintedanib DPI for Pulmonary Fibrosis
04 Nov 2024 //
GLOBENEWSWIRE
MannKind to Host Q3 2024 Results Call on Nov 7, 2024
31 Oct 2024 //
GLOBENEWSWIRE
MannKind Initiates Phase 3 Trial in Australia for NTM Lung Disease
30 Oct 2024 //
GLOBENEWSWIRE
Type 1 Diabetes Patients Achieve A1C Goal With Inhaled Insulin
30 Sep 2024 //
GLOBENEWSWIRE
MannKind To Start Phase 3 NTM Trial In Japan
18 Sep 2024 //
GLOBENEWSWIRE
MannKind To Present At Cantor Healthcare Conference
10 Sep 2024 //
GLOBENEWSWIRE
MannKind to Present at Upcoming Conferences
27 Aug 2024 //
GLOBENEWSWIRE
Kent Kresa To Retire From MannKind Board, Steven Binder To Join Board
14 Aug 2024 //
GLOBENEWSWIRE
MannKind Reports Q2 2024 Results And Provides Clinical Development Update
07 Aug 2024 //
GLOBENEWSWIRE
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
31 Jul 2024 //
GLOBENEWSWIRE
MannKind To Hold Q2 2024 Results Call On August 7
30 Jul 2024 //
GLOBENEWSWIRE
INHALE-3 Inhaled Insulin vs. Usual Care T1D ADA 84th Session
22 Jun 2024 //
GLOBENEWSWIRE
Inhale-3 Results: 90-Min ADA Symposium On June 22
05 Jun 2024 //
GLOBENEWSWIRE
MannKind Expands Inhalation Portfolio, Boston R&D Site Via Pulmatrix Deal
29 May 2024 //
GLOBENEWSWIRE
MannKind Q1 2024 Financials, Clinical Development Update
08 May 2024 //
GLOBENEWSWIRE
MannKind`s Clofazimine Gets FDA Fast Track For NTM Lung Disease
06 May 2024 //
GLOBENEWSWIRE
MannKind Q1 2024 Results Call On May 8
01 May 2024 //
GLOBENEWSWIRE
MannKind to Proceed with Ph1 Nintedanib DPI (MNKD-201) in PF
30 Apr 2024 //
GLOBENEWSWIRE
MannKind Gets IND Clearance for Ph3 Clofazimine in NTM Lung Disease
29 Apr 2024 //
GLOBENEWSWIRE
MannKind Repays Certain Debt Obligations
03 Apr 2024 //
GLOBENEWSWIRE
MannKind Announces CFO Transition
26 Mar 2024 //
GLOBENEWSWIRE
INHALE-3 Study™s Initial Meal Challenge Results Comparing Afrezza®
11 Mar 2024 //
GLOBENEWSWIRE
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented
05 Mar 2024 //
GLOBENEWSWIRE
MannKind Corporation Announces Participation at Upcoming Conferences
04 Mar 2024 //
GLOBENEWSWIRE
MannKind Reports 2023 Fourth Quarter and Full Year Financial Results
27 Feb 2024 //
GLOBENEWSWIRE
MannKind to Hold 2023 Fourth Quarter and Full Year Financial Results Conference
20 Feb 2024 //
GLOBENEWSWIRE
MannKind Announces Enrollment Completion of INHALE-1 Pediatric Diabetes Trial
15 Feb 2024 //
GLOBENEWSWIRE
MannKind and Sagard Enter Into Royalty Purchase Agreement for Up to $200 Million
02 Jan 2024 //
GLOBENEWSWIRE
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
28 Dec 2023 //
GLOBENEWSWIRE
MannKind Corporation Reports 2023 Third Quarter Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
MannKind Announces Completion of Enrollment in U.S. Phase 4 Trial
06 Nov 2023 //
GLOBENEWSWIRE
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference
31 Oct 2023 //
GLOBENEWSWIRE
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
30 Oct 2023 //
GLOBENEWSWIRE
MannKind Corporation Announces Participation at Upcoming Conferences
05 Sep 2023 //
GLOBENEWSWIRE
MannKind Corporation Reports 2023 Second Quarter Financial Results
07 Aug 2023 //
PRESS RELEASE
MannKind Announces Participation in 2023 Wedbush PacGrow Healthcare Conference
01 Aug 2023 //
GLOBENEWSWIRE
MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference
31 Jul 2023 //
GLOBENEWSWIRE
MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today
22 Jun 2023 //
GLOBENEWSWIRE
Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone
11 Jun 2023 //
GLOBENEWSWIRE
Dr. Burkhard Blank Joins MannKind as Executive Vice President of R&d & CMO
24 May 2023 //
GLOBENEWSWIRE
MannKind Corporation to Participate in the 2023 RBC Capital Markets Conference
10 May 2023 //
GLOBENEWSWIRE
CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results
09 May 2023 //
GLOBENEWSWIRE
Mannkind Corporation Reports 2023 First Quarter Financial Results
09 May 2023 //
GLOBENEWSWIRE
MannKind Corporation to Hold 2023 1Q FYR Conference Call on May 9, 2023
02 May 2023 //
GLOBENEWSWIRE
Lauren Sabella Joins Mannkind as Executive VP, Chief Operating Officer
27 Mar 2023 //
GLOBENEWSWIRE
MannKind to Participate in Oppenheimer 33rd Annual Healthcare Conference
07 Mar 2023 //
GLOBENEWSWIRE
MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results
23 Feb 2023 //
GLOBENEWSWIRE
MannKind to Give Presentation on Meal Challenge Results From the Afrezza
22 Feb 2023 //
GLOBENEWSWIRE
MannKind to Hold 2022 Fourth Quarter and Full Year Financial Results
16 Feb 2023 //
GLOBENEWSWIRE
Mannkind to Participate in the SVB Securities Global Biopharma Conference
10 Feb 2023 //
GLOBENEWSWIRE
MannKind to Participate in the Lytham Partners Investor Select Conference
24 Jan 2023 //
GLOBENEWSWIRE
MannKind`s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study
23 Jan 2023 //
GLOBENEWSWIRE
MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference
05 Jan 2023 //
GLOBENEWSWIRE
MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting
10 Nov 2022 //
GLOBENEWSWIRE
MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference
01 Nov 2022 //
GLOBENEWSWIRE
MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor
21 Sep 2022 //
GLOBENEWSWIRE
Mannkind wraps up phase 1 trial of inhaled lung infection asset
06 Sep 2022 //
FIERCEPHARMA
Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine
06 Sep 2022 //
GLOBENEWSWIRE
